SRI teams with Kalekona to deliver therapies aimed at diagnosing and treating pancreatic cancer and glioblastoma
SRI’s FOX Three peptide platform to deliver precision radionuclide therapy targeted at hard-to-treat tumors. MENLO PARK, CA, UNITED STATES, October 21, 2025 /EINPresswire.com/ -- SRI today announced that it formed a strategic partnership with Kalekona …